Drugs / Odiparcil
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00437242 | Oct 2006 → ? | atrial fibrillation | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03370653 | Dec 2017 → Sep 2019 | mucopolysaccharidosis type 6 | Inventiva Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00244725 | Sep 2005 → Sep 2006 | atrial fibrillation, pulmonary embolism, venous thromboembolism | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Odiparcil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03370653 ↗ |
| Known as | Odiparcilo | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107763 ↗ |
| Modality | Small molecule | — CHEMBL2107763 ↗ |
| Route | Oral | “Repeat Oral Doses of Odiparcil” NCT00437242 ↗ |